• Recruiting

NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction & Lenalidomide Maint

Updated: May 24


NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM


CyborD

A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM


A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma


This is a phase II multi-center, open label, single arm study to evaluate the safety and efficacy of Isatuximab administered intravenously in combination with CyBorD induction treatment and Lenalidomide maintenance treatment in a 28-day long cycle in autologous stem cell transplant-eligible patients.


Sponsor

Canadian Myeloma Research Group


Location

Canada

 

ClinicalTrials.gov Identifier: NCT04786028


Official Title: A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma


First Posted: March 8, 2021


Click here to see details on ClinicalTrials.gov

 

Isatuximab : National Cancer Institute

 

Locations

Canada, Alberta

Canada, Manitoba

Canada, Newfoundland and Labrador

Canada, Nova Scotia

Canada, Ontario

Canada, Saskatchewan


Posts Archive